Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

September 3, 2020
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 03 September 2020, 07:00 CEST   POSEIDON – Implants in Canada continue; interim results expected H1 2021 RED DESERT – Implants continue; interim results expected Q4 2020 DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and Europe Continued growth in European commercial implants Secured additional funding...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES